— PeriGen Marks Qualcomm Life’s First Foray into Obstetrics —
Qualcomm Incorporated (NASDAQ:QCOM), through its wholly owned subsidiary, Qualcomm Life, Inc., today announced a strategic reseller agreement with PeriGen, a company that offers innovative, FDA-cleared perinatal software solutions that provide labor and delivery clinicians with enriched patient data based on intelligent algorithms and analysis. Qualcomm Life will be marketing and selling PeriGen’s suite of intelligent care applications that leverage data from connected devices inside the walls of the hospital to provide insights for care teams.
The collaboration with PeriGen will allow Qualcomm Life to license and sell PeriWatch™ Vigilance™, a new early warning platform for obstetrics that automatically identifies patients whose conditions are worsening, facilitating more timely interventions. PeriWatch™ Vigilance™ augments currently installed fetal surveillance systems, providing a critical layer of patient safety without requiring a hospital to “rip and replace” current systems. The “always on” software uses proprietary intelligent algorithms to analyze maternal vital signs, fetal heart rate, contractions and labor progress in real time, informing clinicians of emerging abnormalities. Specific thresholds and automated checklists can be configured according to each institution’s preferences. PeriGen’s solution will complement Qualcomm Life’s Capsule™ product line to make care inside the hospital more intelligent by leveraging connected device and system data.
“As we grow our intelligent care product platform, we look to collaborate with companies that monitor patients and provide actionable insights for physicians and care teams,” said James Mault, MD, FACS, senior vice president and chief medical officer, Qualcomm Life, Inc. “Our collaboration with PeriGen marks the first of Qualcomm Life’s obstetric applications and we are thrilled to be able to work with PeriGen in an effort to garner new insights that enable providers to deliver better care to their patients.”
“Clinicians are increasingly required to multitask, so Vigilance focuses expressly on real-time data analysis to help them quickly and consistently identify circumstances that may require intervention,” said Matthew Sappern, chief executive officer, PeriGen. “We are excited to collaborate with Qualcomm Life, a company with the same vision of leveraging medical device data to the benefit of patients and their care teams.”
Qualcomm invents breakthrough technologies that transform how the world connects and communicates. When we connected the phone to the Internet, the mobile revolution was born. Today, our inventions are the foundation for life-changing products, experiences, and industries. As we lead the world to 5G, we envision this next big change in cellular technology spurring a new era of intelligent, connected devices and enabling new opportunities in connected cars, remote delivery of health care services, and the IoT — including smart cities, smart homes, and wearables. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, all of our engineering, research and development functions, and all of our products and services businesses, including, the QCT semiconductor business. For more information, visit Qualcomm’s website, OnQ blog, Twitter and Facebook pages.
PeriGen offers innovative perinatal software solutions that incorporate artificial intelligence (AI) features to enhance clinical efficiency and standardization of care during childbirth. Led by skilled OB practitioners and IT visionaries, PeriGen has created the PeriWatch platform to provide consistent analysis and efficient display of complex data in real-time to promote better human recognition and communication about impending problems during labor. With PeriWatch clinicians can spend more time on direct patient care and less time on manual calculations and data manipulation. To learn more, visit www.perigen.com; follow us on Twitter, LinkedIn, YouTube, and Facebook; or call 984.208.4250 or email.